Photodynamic Diagnosis Ups Detection of BCG-Refractory Bladder Tumors
Photodynamic diagnosis cystoscopy demonstrates greater sensitivity in the detection of BCG-refractor bladder tumors compared with standard white light cystoscopy.
Bladder Cancer News
BLADDER CANCER ADVISOR
Bladder Cancer News
Survival Odds Similar After Open, Robotic-Assisted Radical Cystectomy
Researchers in The Netherlands compared the surgical approaches in patients with muscle-invasive or high-risk nonmuscle-invasive bladder cancer.
Photodynamic Diagnosis May Reduce NMIBC Recurrence Rates
Before PDD TURBT can be adopted into clinical practice, a large pragmatic trial is needed, according to investigators.
Women Have Worse Oncologic Outcomes in High-Risk NMIBC
Among patients with high-risk pTa bladder cancer, female sex was significantly associated with a higher risk for stage progression compared with male sex.
Younger Patients Less Likely to Die From NMIBC
The investigators found no significant age-related differences in survival from muscle-invasive bladder cancer.
Padcev Gets Full Approval, Expanded Indication for Urothelial Cancer
Full approval was granted based on overall survival data from a confirmatory trial.
Adjuvant Nivolumab Improves Disease-Free Survival in High-Risk Muscle-Invasive Urothelial Carcinoma
Improvements were seen regardless of PD-L1 expression.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Bevacizumab Does Not Provide a Survival Benefit in Metastatic Bladder Cancer
There was a significant improvement in progression-free survival with bevacizumab, but it was not considered clinically meaningful.
No Benefit With Adjuvant Atezolizumab in Muscle-Invasive Urothelial Carcinoma
The aim of the trial was to determine if adjuvant atezolizumab improved disease-free survival.
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
High Body Mass Index Is a Risk Factor for Gallbladder and Biliary Tract Cancer Mortality
A decrease in obesity rates may reduce the burden of gallbladder and biliary tract cancer worldwide, according to the results of a study.
Ureteroscopic Biopsy in UTUC May Increase Risk of Intravesical Recurrence
Compared with no ureteroscopy or percutaneous biopsy, ureteroscopic biopsy in patients with upper tract urothelial carcinoma was significantly associated with a 40% increased risk for intravesical recurrence of disease.
Complete TURBT Before Neoadjuvant Chemotherapy Improves MIBC Outcomes
Complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy in patients scheduled to undergo radical cystectomy for muscle-invasive bladder is associated with improved overall and cancer-specific survival, a study found.
Prophylactic Ureteral Stenting Linked to Upper Tract Urothelial Carcinoma
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
Trodelvy Gets Accelerated Approval for Urothelial Cancer
The accelerated approval was based on data from the multicenter, open-label, phase 2 TROPHY study.
Seminal Vesicle-Sparing in Radical Cystectomy Shown to Improve Outcomes
Seminal vesicle-sparing radical cystectomy improved functional results over a median of 64 months without compromising oncologic outcomes, according to investigators.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...